Dr. John Cush RheumNow
3 years 6 months ago
Renal Involvement is Pivotal in ANCA-Associated Vasculitis
Researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.
https://t.co/O8EaW2MaBx https://t.co/VApYiH66yn
Dr. John Cush RheumNow
3 years 6 months ago
ENT involvement studied in 320 ANCA associated vasculitis pts: 65% had ENT involvement w/ median age =52 yrs, & median BVAS3 = 12. Relapse seen in 29% despite immunosupp Rx. No diff in outcomes betw pts Rx w/ oral or IV CTX or RTX https://t.co/MwZSnVVd32 https://t.co/YbrHxnqDw9
Dr. John Cush RheumNow
3 years 6 months ago
Systemic sclerosis current therapy:
- early dcSSc: MMF, CTX, RTX, TCZ
- rapidly progressive dcSSc - ?Stem cell transpl?
- SSc-ILD: MMF>CTX, possibly nintedanib, perfinidone
- Raynauds w/ digital ulcers: CA channel block, PDE5 inhib, iloprost, Bosentan https://t.co/87giuQR4YZ https://t.co/z2TPlJnu5e
Dr. John Cush RheumNow
3 years 6 months ago
Long-Term Benefit of Rituximab in Systemic Sclerosis
A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
https://t.co/f68wc6lQGH https://t.co/G4PKPnJ0LJ
Dr. John Cush RheumNow
3 years 6 months ago
I Wanna Get Pregnant
https://t.co/zOkchWO3XQ https://t.co/KhY5obavkW
Dr. John Cush RheumNow
3 years 6 months ago
Managing Septic Arthritis in RA
https://t.co/ccRZLCtl3S https://t.co/wS2KG1jAJl
Dr. John Cush RheumNow
3 years 6 months ago
QD Clinic - Double Positive, but Few Joints
Lessons from the clinic brought to you by RheumNow Live, March 18 &19, 2023 - Dallas, TX
https://t.co/jnKuJbPG7l https://t.co/SiTaAXe6II
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
There has been considerable debate whether established cutaneous psoriasis patients can avert or lessen the risk of future inflammatory arthritis if treated aggressively with biologic therapy.
Dr. John Cush RheumNow
3 years 6 months ago
Recurrent Fevers; 3 Days at 103F QD Clinic - Lessons from the clinic, brought to you by RheumNow Live March 18 &19, 2023 - Dallas, TX https://t.co/pWrCVrxamD https://t.co/C6q9aVJ2gg
Dr. John Cush RheumNow
3 years 6 months ago
NSAIDs in Pregnancy
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
https://t.co/uCKNXV1zGF https://t.co/RbutI3PBjq
Dr. John Cush RheumNow
3 years 6 months ago
Serum beta-2 microglobulin (B2M) in 100 #SLE pts - strong correlations betw B2M & 24 hr urinary protein, BUN, creatinine, disease activity, & damage score (p < 0.001), & negatively correlated with GFR, C3, C4 (p < 0.001). B2M predicted lupus LN https://t.co/XujdKvjjoS https://t.co/vl8XXQDhXM
Dr. John Cush RheumNow
3 years 6 months ago
2017 Prevalence of Psoriatic arthritis (PsA) in Sweden estimated to be 0.34% (range 0.32-0.50% across all sensitivity analyses); lower in males & w/ higher level of education. 0.24% have seen rheumatology care- 32% on b/ts-DMARDs, 41% csDMARDs https://t.co/Jh2WUYVJR2 https://t.co/ZdFVIq2iQ0
Dr. John Cush RheumNow
3 years 6 months ago
ARTIS Swedish study of Cancer in RA or PSA pts (~15k pts) starting JAKi vs TNFi. With ~2 yrs F/U, the risk of Cancer (excluding NMSC) was similar betw JAKi and TNFi (HR 0.94; 0.65 to 1.38), but more incident NMSC w/ JAKi (HR 2.12; 1.15 to 3.89) at 2 yrs https://t.co/BiPWF1T0lZ https://t.co/nrmaCGBcce
A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
